Control of influenza and poliomyelitis with killed virus vaccines - PubMed (original) (raw)

Review

Control of influenza and poliomyelitis with killed virus vaccines

J Salk et al. Science. 1977.

Abstract

The requirements for inducing immunity against an infectious disease are outlined, and the application of these requirements to the development of effective vaccines (vaccinology) is discussed. Influenza and poliomyelitis are examined from this viewpoint, and data are presented that demonstrate the effectiveness of killed virus vaccines against these diseases. A comparison between live and killed poliovirus vaccines suggests the desirability of returning to the use of a killed virus vaccine for the eradication of polio. The natural history of influenza and experience with vaccination suggest that influenza might be brought under effective control by routine immunization in childhood with a polyvalent killed virus vaccine potentiated by an immunologic adjuvant.

PubMed Disclaimer

Similar articles

• Vaccinology of poliomyelitis.
  Salk D, Salk J. Salk D, et al. Vaccine. 1984 Mar;2(1):59-74. doi: 10.1016/s0264-410x(98)90035-4. Vaccine. 1984. PMID: 6099644 Review.
• Eradication of poliomyelitis in the United States. III. Poliovaccines--practical considerations.
  Salk D. Salk D. Rev Infect Dis. 1980 Mar-Apr;2(2):258-73. doi: 10.1093/clinids/2.2.258. Rev Infect Dis. 1980. PMID: 6994208 Review.
• Immunization against poliomyelitis: risk/benefit/cost in a changing context.
  Salk J. Salk J. Dev Biol Stand. 1979;43:151-7. Dev Biol Stand. 1979. PMID: 230106
• Decision analysis in planning for a polio outbreak in the United States.
  Jenkins PC, Modlin JF. Jenkins PC, et al. Pediatrics. 2006 Aug;118(2):611-8. doi: 10.1542/peds.2005-2358. Pediatrics. 2006. PMID: 16882814
• Recommendations for a national policy on poliomyelitis vaccination.
  Nightingale EO. Nightingale EO. N Engl J Med. 1977 Aug 4;297(5):249-53. doi: 10.1056/NEJM197708042970505. N Engl J Med. 1977. PMID: 195207

Cited by

• Nanoparticles and Antiviral Vaccines.
  Liu S, Hu M, Liu X, Liu X, Chen T, Zhu Y, Liang T, Xiao S, Li P, Ma X. Liu S, et al. Vaccines (Basel). 2023 Dec 27;12(1):30. doi: 10.3390/vaccines12010030. Vaccines (Basel). 2023. PMID: 38250843 Free PMC article. Review.
• Preventing monkeypox outbreaks: Focus on diagnosis, care, treatment, and vaccination.
  Ghaseminia M. Ghaseminia M. J Clin Transl Sci. 2023 Feb 3;7(1):e60. doi: 10.1017/cts.2023.11. eCollection 2023. J Clin Transl Sci. 2023. PMID: 37008622 Free PMC article. Review.
• Development of a Purified Viral Preparation for Studies of COVID-19 (SARS-CoV-2) Biology.
  Chepurnov AA, Kazachinskaya EI, Kazachkova EA, Sharshov KA, Kononova YV, Shelemba AA, Alekseev AY, Gulyeva MA, Voevoda MI, Shestopalov AM. Chepurnov AA, et al. Bull Exp Biol Med. 2021 Nov;172(1):49-52. doi: 10.1007/s10517-021-05329-7. Epub 2021 Nov 17. Bull Exp Biol Med. 2021. PMID: 34787781 Free PMC article.
• Chapter 4 Picornavirus infections.
  [No authors listed] [No authors listed] Perspect Med Virol. 1985;1:127-186. doi: 10.1016/S0168-7069(08)70012-0. Epub 2008 May 29. Perspect Med Virol. 1985. PMID: 32287579 Free PMC article.
• The PathLink Acquired Gestational Tissue Bank: Feasibility of Project PLACENTA.
  Linder JE, Batey K, Johnston R, Cohen EM, Wang Y, Wang X, Zaleski NM, Rogers LM, McDonald WH, Reyzer ML, Judd A, Goldstein J, Correa H, Pulley J, Aronoff DM. Linder JE, et al. J Reprod Biotechnol Fertil. 2018;7:14-27. J Reprod Biotechnol Fertil. 2018. PMID: 30637122 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information